These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23296022)

  • 1. SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients.
    Schif B; Lennerz JK; Kohler CW; Bentink S; Kreuz M; Melzner I; Ritz O; Trümper L; Loeffler M; Spang R; Möller P
    Oncotarget; 2013 Jan; 4(1):35-47. PubMed ID: 23296022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma.
    Lennerz JK; Hoffmann K; Bubolz AM; Lessel D; Welke C; Rüther N; Viardot A; Möller P
    Oncotarget; 2015 Oct; 6(30):29097-110. PubMed ID: 26336985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
    Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
    J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of SOCS1 mutations in diffuse large B-cell lymphoma.
    Mellert K; Martin M; Lennerz JK; Lüdeke M; Staiger AM; Kreuz M; Löffler M; Schmitz N; Trümper L; Feller AC; Hartmann S; Hansmann ML; Klapper W; Stein H; Rosenwald A; Ott G; Ziepert M; Möller P
    Br J Haematol; 2019 Dec; 187(5):627-637. PubMed ID: 31407320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural analysis and conformational dynamics of SOCS1 gene mutations involved in diffuse large B-cell lymphoma.
    Dristy TT; Noor AR; Dey P; Saha A
    Gene; 2023 May; 864():147293. PubMed ID: 36813059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.
    Lacy SE; Barrans SL; Beer PA; Painter D; Smith AG; Roman E; Cooke SL; Ruiz C; Glover P; Van Hoppe SJL; Webster N; Campbell PJ; Tooze RM; Patmore R; Burton C; Crouch S; Hodson DJ
    Blood; 2020 May; 135(20):1759-1771. PubMed ID: 32187361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of DLBCL with a PMBL gene expression signature.
    Duns G; Viganò E; Ennishi D; Sarkozy C; Hung SS; Chavez E; Takata K; Rushton C; Jiang A; Ben-Neriah S; Woolcock BW; Slack GW; Hsi ED; Craig JW; Hilton LK; Shah SP; Farinha P; Mottok A; Gascoyne RD; Morin RD; Savage KJ; Scott DW; Steidl C
    Blood; 2021 Jul; 138(2):136-148. PubMed ID: 33684939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diffuse large B-cell lymphoma.
    Li S; Young KH; Medeiros LJ
    Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
    Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
    Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
    Bohers E; Mareschal S; Bouzelfen A; Marchand V; Ruminy P; Maingonnat C; Ménard AL; Etancelin P; Bertrand P; Dubois S; Alcantara M; Bastard C; Tilly H; Jardin F
    Genes Chromosomes Cancer; 2014 Feb; 53(2):144-53. PubMed ID: 24327543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
    Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
    Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.
    Choi WW; Weisenburger DD; Greiner TC; Piris MA; Banham AH; Delabie J; Braziel RM; Geng H; Iqbal J; Lenz G; Vose JM; Hans CP; Fu K; Smith LM; Li M; Liu Z; Gascoyne RD; Rosenwald A; Ott G; Rimsza LM; Campo E; Jaffe ES; Jaye DL; Staudt LM; Chan WC
    Clin Cancer Res; 2009 Sep; 15(17):5494-502. PubMed ID: 19706817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing.
    Trabucco SE; Sokol ES; Maund SL; Moore JA; Frampton GM; Albacker LA; Oestergaard MZ; Venstrom J; Sehn LH; Bolen CR
    Future Oncol; 2021 Nov; 17(31):4171-4183. PubMed ID: 34313135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 15. A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas.
    van der Meeren LE; Kluiver J; Rutgers B; Alsagoor Y; Kluin PM; van den Berg A; Visser L
    PLoS One; 2019; 14(10):e0223260. PubMed ID: 31603917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
    Dunleavy K; Pittaluga S; Czuczman MS; Dave SS; Wright G; Grant N; Shovlin M; Jaffe ES; Janik JE; Staudt LM; Wilson WH
    Blood; 2009 Jun; 113(24):6069-76. PubMed ID: 19380866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.
    Xia Y; Xu-Monette ZY; Tzankov A; Li X; Manyam GC; Murty V; Bhagat G; Zhang S; Pasqualucci L; Visco C; Dybkaer K; Chiu A; Orazi A; Zu Y; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Westin J; Fowler N; Miranda RN; Ok CY; Li Y; Li J; Medeiros LJ; Young KH
    Leukemia; 2017 Mar; 31(3):625-636. PubMed ID: 27568520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
    Yang JM; Jang JY; Jeon YK; Paik JH
    J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
    Lenz G; Wright GW; Emre NC; Kohlhammer H; Dave SS; Davis RE; Carty S; Lam LT; Shaffer AL; Xiao W; Powell J; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Campo E; Jaffe ES; Delabie J; Smeland EB; Rimsza LM; Fisher RI; Weisenburger DD; Chan WC; Staudt LM
    Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13520-5. PubMed ID: 18765795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma.
    Iqbal J; Greiner TC; Patel K; Dave BJ; Smith L; Ji J; Wright G; Sanger WG; Pickering DL; Jain S; Horsman DE; Shen Y; Fu K; Weisenburger DD; Hans CP; Campo E; Gascoyne RD; Rosenwald A; Jaffe ES; Delabie J; Rimsza L; Ott G; Müller-Hermelink HK; Connors JM; Vose JM; McKeithan T; Staudt LM; Chan WC;
    Leukemia; 2007 Nov; 21(11):2332-43. PubMed ID: 17625604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.